Raymond Prudo-Chlebosz

CIK: 0001653262

Transaction Breakdown

Open Market Buys (P)4 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (60.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AKTX

Akari Therapeutics Plc

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

AKTX
Akari Therapeutics Plc
Oct 5, 2026
Award(A)
Direct
3.2K shares at avg. $7.90$26K
AKTX
Akari Therapeutics Plc
Aug 18, 2026
Award(A)
Direct
9.1K shares at avg. $7.90$72K
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Pre-Funded Warrants to purchase ADRs
Direct
618.7K shares at avg. $0.40-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Warrants to purchase American Depositary Shares ("ADRs")
Direct
618.7K shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Warrants to purchase ADRs
Direct
386.7K shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Pre-Funded Warrants to purchase ADRs
Direct
386.7K shares at avg. $0.40-
AKTX
Akari Therapeutics Plc
Mar 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
175K shares-
AKTX
Akari Therapeutics Plc
Mar 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
225K shares-
AKTX
Akari Therapeutics Plc
Mar 6, 2025
Award(A)
Direct
446.4K shares at avg. $1.12$500K
AKTX
Akari Therapeutics Plc
Dec 2, 2024
Award(A)
Direct
419.3M shares at avg. $0.00$503K

		Type	Shares	Price		Ownership
Oct 5, 2026	AKTX Akari Therapeutics Plc	Award(A)	3,240	$7.90	$25,593	Direct
Aug 18, 2026	AKTX Akari Therapeutics Plc	Award(A)	9,072	$7.90	$71,660	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Pre-Funded Warrants to purchase ADRs	618,658	$0.40	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Warrants to purchase American Depositary Shares ("ADRs")	618,658	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Warrants to purchase ADRs	386,661	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Pre-Funded Warrants to purchase ADRs	386,661	$0.40	-	Direct
Mar 20, 2025	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	175,000	-	-	Direct
Mar 20, 2025	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	225,000	-	-	Direct
Mar 6, 2025	AKTX Akari Therapeutics Plc	Award(A)	446,428	$1.12	$499,999	Direct
Dec 2, 2024	AKTX Akari Therapeutics Plc	Award(A)	419,286,000	$0.00	$503,143	Direct

1-10 of 10 transactions

About Prudo-Chlebosz Raymond

Prudo-Chlebosz Raymond (SEC CIK 0001653262) files insider reports with the SEC as Director of Akari Therapeutics Plc (AKTX).

Signal8 holds 5 ownership filings by Prudo-Chlebosz Raymond, all Form 4s, filed between Dec 3, 2024 and Oct 16, 2026. Those filings report 10 transactions, from Dec 2, 2024 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Prudo-Chlebosz Raymond's filings is in TAMPA, FL.

Recent filings by Prudo-Chlebosz Raymond

Oct 5, 2026: Grant or award of AKTX shares (Form 4, code A).
Aug 18, 2026: Grant or award of AKTX shares (Form 4, code A).
Dec 16, 2025: Open-market purchases of AKTX derivative securities (4 lines, Form 4, code P).
Mar 20, 2025: Grants or awards of AKTX derivative securities (2 lines, Form 4, code A).
Mar 6, 2025: Grant or award of AKTX shares (Form 4, code A).

Other insiders filing for Akari Therapeutics Plc (AKTX)

Huh Hoyoung, Director
Patel Sandip I, Director
Bazemore Robert B, Director
Gaslightwala Abizer, CEO
Patel Samir Rashmikant, Director
Vat-Ho Vatnak, Chief Business Officer

How to read Form 4 transaction codes